Loading...
Symbols:
Loading...
Symbols:
Simcere Pharmaceutical Group (SCR)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Simcere Pharmaceutical Group (SCR)
36 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on SCR
- ChinaBio Today(22)
- The Sun(3)
- Timothy Roe(2)
- Centient Biotech Investor(2)
- SA Editors(1)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(572)
- Stockerblog (162)
- SA Editor Miriam Metzinger(116)
- Martin Hutchinson(96)
- ChinaBio Today(61)
Most commented on authors
- The Sun(16)
- ChinaBio Today(8)
- Martin Hutchinson(6)
- Bespoke Investment Group(5)
- Stockerblog (4)
- China Bio in Review: More Fallout from Economic Crisis
- Investors Liked What They Saw in Simcere's Q3 Report
- China Bio Week-in-Review: Trials and Deals
- Simcere Shows Positive Data from Cancer Drug Trial
- Six Key Chinese Healthcare ADRs
- China ADRs: Mixed July
- Simcere’s Q2 Fails Expectations
- Global Investing, BRIC by BRIC: Part II
- China ADRs: Severe Loss in June
- China Biopharma Growth Metrics
- Simcere Granted SFDA Approval for Generic Antibiotic
- China Biopharma: What’s Not to Like?
- Simcere’s Q1: Revenue Increases 26%
- Biotech in Review: Investments in China Drug Development
- Simcere Buys Cancer Drug Company
- Simcere Books Solid 2007
- Simcere Pharmaceutical Gains on Strong Earnings
- China Biotech Week in Review: East-West Interdependence in 2007
- Biotech Week in Review: Cross Border China Pharma Activity
- Simcere Acquires New Cancer Drug; Misses on Q3 Revenue
- Reviewing A Good Week for China BioPharma Investment
- Simcere Pharma's Q3 Did No More Than Meet Expectations
- Simcere Reports Unimpressive Q3 Results
- It's More than Just Baidu: 51 Other Ways to Invest in China
- Recent Chinese IPOs Continue To Shine
- Best, Worst Performing Chinese ADRs YTD
- Simcere Invests Heavily in Rival Boda
- Biotech Week in Review: Sector Consolidation in China
- Recently Listed Simcere, Tongjitang Appear Attractively Priced
- Post IPO: Simcere Announces Q2 Earnings and Posts Higher Revenues
- Post-IPO Simcere: Biggest American-Listed Chinese Pharma
- Recent Chinese IPOs On Wall Street - EDU Leads The Pack
- This Week's IPOs: MBF Healthcare, MetroPCS Communications, Simcere Pharmaceuticals, Superior Offshore International
- Biotech IPO Watch: Simcere Supplies High-End Generics In China
- Biotech Week In Review: Positive Territory For 2007
- John Dorfman's Five Picks Between $5-$10
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »